AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg twice daily
Number of subjects: 424
Study 11498212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study 11498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast 5 mg and 10 mg
Number of subjects: 424
Study 9862014 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint (Zusanli acupoints)
Number of subjects: 13
Study 9862014 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoints formula (Zusanli and Shousanli acupoints)
Number of subjects: 13
Study 9862014 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint (2 cm lateral to Zusanli acupoints)
Number of subjects: 13
Study 9862014 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint vs Acupoints formula
Number of subjects: 13
Study 8867157 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses (90 D, Adatomed or C 10, Chiron)
Number of subjects: 815
Study 8867157 — intervention group
Group type: COMPARATOR
Intervention: One-piece PMMA intraocular lens
Number of subjects: 815
Study 8867157 — intervention group
Group type: EXPERIMENTAL
Intervention: All three types of IOLs
Number of subjects: 815
Study 1690481 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 156
Study 1690481 — intervention group
Group type: COMPARATOR
Intervention: Paraprost
Number of subjects: 156
Study 7416907 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 105
Study 7416907 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 105
Study 7416907 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study 31789950 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest in type-2 diabetes
Number of subjects: 505
Study 31789950 — intervention group
Group type: COMPARATOR
Intervention: FibroTest in controls
Number of subjects: 505
Study 31789950 — intervention group
Group type: EXPERIMENTAL
Intervention: SteatoTest-2 in type-2 diabetes
Number of subjects: 505
Study 31789950 — intervention group
Group type: COMPARATOR
Intervention: SteatoTest-2 in controls
Number of subjects: 505
Study 31789950 — intervention group
Group type: EXPERIMENTAL
Intervention: NashTest-2 in type-2 diabetes
Number of subjects: 505
Study 31789950 — intervention group
Group type: COMPARATOR
Intervention: NashTest-2 in controls
Number of subjects: 505
Study 31789950 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography
Number of subjects: 505
Study 31789950 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography
Number of subjects: 505
Study 31789950 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 505
Study 30422909 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective risk score (CalcR) provided to intervention arm participants
Number of subjects: 171
Study 30422909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no objective risk score provided)
Number of subjects: 171
Study 30422909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 171
Study 27500370 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solutions of surfactants (anionic, non-ionic, amphoteric)
Number of subjects: 20
Study 25867693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 41
Study 25867693 — intervention group
Group type: COMPARATOR
Intervention: Self-help CBT-I (written materials only)
Number of subjects: 41
Study 25930115 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine ointment (PIO) applied starting on post-vaccination day 7
Number of subjects: 60
Study 25930115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PIO)
Number of subjects: 60
Study 25930115 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine ointment (PIO)
Number of subjects: 60
Study 25930115 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine ointment (PIO) and control group
Number of subjects: 60
Study 23220343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program (3-month duration including 8 weeks of exercise training, health education, home hazards evaluation/modification, medication review, and specialty consults)
Number of subjects: 616
Study 23220343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program
Number of subjects: 616
Study 23220343 — intervention group
Group type: COMPARATOR
Intervention: Control group (health education brochures, referrals, and recommendations without direct exercise intervention)
Number of subjects: 616
Study 23220343 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 616
Study 21241789 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release microparticles F-3 (TmH:EC ratio 1:2)
Number of subjects: 0
Study 21241789 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release microparticles F-4 (TmH:EC ratio 1:3)
Number of subjects: 0
Study 21241789 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release formulation (control)
Number of subjects: 0
Study 17611168 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Across the Curriculum (PAAC) intervention, incorporating moderate-intensity PA into standard academic lessons, with a target of 90-100 min/week over 3 years.
Number of subjects: 22
Study 17611168 — intervention group
Group type: COMPARATOR
Intervention: Control group, which did not alter their teaching methods.
Number of subjects: 22
Study 16492621 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 47
Study 12970142 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and energy dense supplement enriched with n‐3 fatty acids and antioxidants (E)
Number of subjects: 200
Study 12970142 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous control supplement (C)
Number of subjects: 200
Study 10852980 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 12-week aerobic exercise class
Number of subjects: 74
Study 10852980 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home aerobic exercises
Number of subjects: 74
Study 9515594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (i.v.IG) 1 g/kg body weight
Number of subjects: 31
Study 9515594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous human serum albumin)
Number of subjects: 31
Study 9515594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (i.v.IG)
Number of subjects: 31
Study 8036475 — intervention group
Group type: EXPERIMENTAL
Intervention: loracarbef (200 mg b.i.d. for 7 days)
Number of subjects: 80
Study 8036475 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin (500 mg t.i.d. for 7 days)
Number of subjects: 80
Study 8036475 — intervention group
Group type: EXPERIMENTAL
Intervention: loracarbef
Number of subjects: 80
Study 8036475 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin
Number of subjects: 80
Study 3177262 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTC)
Number of subjects: 44
Study 3177262 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 44
Study 3177262 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DMP)
Number of subjects: 44
Study 31154414 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ mono (Tocilizumab monotherapy)
Number of subjects: 79
Study 31154414 — intervention group
Group type: COMPARATOR
Intervention: TCZ + MTX (Tocilizumab plus Methotrexate)
Number of subjects: 79
Study 29705650 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 140
Study 29705650 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical and device therapy alone (Control)
Number of subjects: 140
Study 28893234 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hours removal of urinary catheter and vaginal pack
Number of subjects: 200
Study 28893234 — intervention group
Group type: COMPARATOR
Intervention: 24 hours removal of urinary catheter and vaginal pack
Number of subjects: 200
Study 26666374 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode therapy (LEDT) administered with a multidiode cluster probe (50 GaAIA LEDs, 850 ηm, 75 mW each diode, and 3 J per point) before exercise sessions.
Number of subjects: 0
Study 26666374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 23257316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesion injections of pingyangmycin in combination with triamcinolone acetonide
Number of subjects: 29
Study 23257316 — intervention group
Group type: COMPARATOR
Intervention: Intralesion injections of pingyangmycin alone
Number of subjects: 29
Study 21989212 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture for two seconds in LI4, administered during six visits to the clinic, twice weekly.
Number of subjects: 90
Study 21989212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture).
Number of subjects: 90
Study 21989212 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture for two seconds in LI4.
Number of subjects: 90
Study 18070940 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 1902
Study 18070940 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 1902
Study 16181792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 36
Study 16181792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12701865 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU/cc of low molecular weight heparin (LMWH) in vitrectomy infusion fluid
Number of subjects: 30
Study 12701865 — intervention group
Group type: COMPARATOR
Intervention: No heparin in the infusion fluid (control group)
Number of subjects: 30
Study 11120505 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 51
Study 11120505 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate
Number of subjects: 51
Study 9229416 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality therapy
Number of subjects: 0
Study 9229416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0
Study 9229416 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical techniques
Number of subjects: 0
Study 9229416 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatments
Number of subjects: 0
Study 9229416 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative management
Number of subjects: 0
Study 7982870 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile Fire Awareness and Intervention Program (education about fire safety and behavior modification)
Number of subjects: 138
Study 7982870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 138
Study 3292159 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent topical minoxidil solution applied twice daily for one year to half the scalp
Number of subjects: 21
Study 3292159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30612532 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion interventions
Number of subjects: 0
Study 30952572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 80
Study 30952572 — intervention group
Group type: COMPARATOR
Intervention: lacto‐ovo‐vegetarian diet (VD)
Number of subjects: 80
Study 28991759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 40
Study 28991759 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 40
Study 25617224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (400,000 IU)
Number of subjects: 44
Study 25617224 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study 25617224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 44
Study 23782178 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (0.2 mg/kg/day)
Number of subjects: 906
Study 23782178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study 23782178 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 906
Study 21416132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy with streptokinase (SK)
Number of subjects: 120
Study 18493312 — intervention group
Group type: EXPERIMENTAL
Intervention: gatifloxacin (10 mg/kg/day)
Number of subjects: 358
Study 18493312 — intervention group
Group type: COMPARATOR
Intervention: azithromycin (20 mg/kg/day)
Number of subjects: 358
Study 18493312 — intervention group
Group type: EXPERIMENTAL
Intervention: gatifloxacin
Number of subjects: 358
Study 18493312 — intervention group
Group type: COMPARATOR
Intervention: azithromycin
Number of subjects: 358
Study 16790698 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (≤2 mg/kg/day)
Number of subjects: 158
Study 16790698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 12955185 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniplas
Number of subjects: 84
Study 12955185 — intervention group
Group type: EXPERIMENTAL
Intervention: Octaplas
Number of subjects: 84
Study 12955185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plasma transfusion)
Number of subjects: 84
Study 11203631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec inlay
Number of subjects: 20
Study 11203631 — intervention group
Group type: EXPERIMENTAL
Intervention: Empress inlay
Number of subjects: 20
Study 11203631 — intervention group
Group type: COMPARATOR
Intervention: Gold inlay
Number of subjects: 20
Study 11203631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inlays (all types)
Number of subjects: 20
Study 11203631 — intervention group
Group type: EXPERIMENTAL
Intervention: All ceramic systems
Number of subjects: 20
Study 9361375 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine infusion
Number of subjects: 2
Study 9361375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-Arginine supplementation
Number of subjects: 2
Study 1558413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric misoprostol (200 micrograms four times a day)
Number of subjects: 127
Study 1558413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus intravenous cimetidine (300 mg every 6 hours)
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Presence of renal failure
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Presence of hepatic failure
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Presence of coagulopathy
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Number of organ system failures at study entry
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Presence of adult respiratory distress syndrome (ARDS)
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Development of upper gastrointestinal hemorrhage (UGIH)
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Number of stress lesions developed
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Additional organ system failure
Number of subjects: 127
Study 1558413 — intervention group
Group type: COMPARATOR
Intervention: Diffuse gastritis
Number of subjects: 127
Study 2983304 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia by the caudal route
Number of subjects: 0
Study 2983304 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with halothane
Number of subjects: 0
Study 30736748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM™) intervention
Number of subjects: 83
Study 28786012 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (n=30)
Number of subjects: 60
Study 28786012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 60
Study 26621366 — intervention group
Group type: EXPERIMENTAL
Intervention: FastFES
Number of subjects: 50
Study 26621366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast
Number of subjects: 50
Study 26621366 — intervention group
Group type: COMPARATOR
Intervention: Self-selected speeds (SS)
Number of subjects: 50
Study 24790277 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline
Number of subjects: 25
Study 24790277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22925596 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT with brief phone support by assistant (5-10 min)
Number of subjects: 200
Study 22925596 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT with extended phone support by assistant (20-30 min)
Number of subjects: 200
Study 22925596 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT with brief phone support by clinician (5-10 min)
Number of subjects: 200
Study 22925596 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT with extended phone support by clinician (20-30 min)
Number of subjects: 200
Study 19809337 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 22
Study 19809337 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (up to 6 mg/day)
Number of subjects: 22
Study 19809337 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 22
Study 19809337 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 22
Study 17906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 200 mg dose of pirfenidone
Number of subjects: 48
Study 17906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of pirfenidone
Number of subjects: 48
Study 17906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 600 mg dose of pirfenidone
Number of subjects: 48
Study 17906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 400 mg pirfenidone administered 3 times daily (tid)
Number of subjects: 48
Study 17906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone with food
Number of subjects: 48
Study 17906160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone without food (fasted)
Number of subjects: 48
Study 16044340 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1,250 mg/m2 twice daily for 14 days, followed by a 7-day rest period, n=10)
Number of subjects: 20
Study 16044340 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/LV (Mayo Clinic regimen: LV 20 mg/m2 followed by 5‐FU 425 mg/m2, administered as an i.v. bolus on days 1‐5 every 28 days, n=10)
Number of subjects: 20
Study 16044340 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 20
Study 16044340 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/LV
Number of subjects: 20
Study 12402370 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program focused on coping with residual and relapse warning signs, managing drug side effects, medication compliance, and daily routines; included self-efficacy method, manuals, videotapes, small group discussions, and telephone coaching
Number of subjects: 38
Study 12402370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 38
Study 10464459 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 6000
Study 10464459 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (laparotomy)
Number of subjects: 6000
Study 7781143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg i.v. before paclitaxel
Number of subjects: 0
Study 7781143 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg i.v. before paclitaxel
Number of subjects: 0
Study 2189483 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic operation using laser
Number of subjects: 140
Study 2189483 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic operation using mechanical instruments
Number of subjects: 140
Study 7273650 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy
Number of subjects: 114
Study 7273650 — intervention group
Group type: COMPARATOR
Intervention: TBI (Total Body Irradiation)
Number of subjects: 114
Study 7273650 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (stratified for Stage III)
Number of subjects: 114
Study 29294507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen (IVA)
Number of subjects: 82
Study 29294507 — intervention group
Group type: COMPARATOR
Intervention: Control (PCA alone)
Number of subjects: 82
Study 28651211 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 43
Study 28651211 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 43
Study 26062183 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-spasm-needle therapy applied to Jiejian, Xuehaishang and Houxuehai, given once every two days for 20 days, with 3 sessions total.
Number of subjects: 140
Study 26062183 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapies (Bobath therapy and lower extremities therapy) and scalp acupuncture (seven‐intelligent needles) in the control group, given once every day for 20 days, with 3 sessions total.
Number of subjects: 140
Study 23415239 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare
Number of subjects: 10854
Study 23415239 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 10854
Study 23415239 — intervention group
Group type: EXPERIMENTAL
Intervention: No insurance
Number of subjects: 10854
Study 23415239 — intervention group
Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 10854
Study 21214919 — intervention group
Group type: EXPERIMENTAL
Intervention: DECISION+ continuing medical education program
Number of subjects: 39
Study 21214919 — intervention group
Group type: EXPERIMENTAL
Intervention: DECISION+ training sessions
Number of subjects: 39